SHP640
Phase 3Small molecule
TakedaSHP640 is one of 24 small molecule programs targeting Viral Conjunctivitis. It is currently in Phase 3.
2
Indications
3
Total Trials
0
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
37 competitors in Bacterial Conjunctivitis
#DrugCompanyPhaseTrials
1Vancocin
HHikma Pharmaceuticals LLC
Approved
Levaquin
WWim Janssens
Approved
Avelox
BayerPhase 3
Tobrex
VViatris Specialty LLC
Phase 3
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Zymar
AbbViePhase 3
Vigamox
Merck & Co.Approved
Besivance
BBausch Health Americas, Inc.
Phase 3
Azasite
Merck & Co.Phase 3
SHP640
TakedaPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Viral Conjunctivitis2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SHP640. EMBL-EBI & Wellcome Sanger Institute.
- [4]